Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

As of June 30, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A carries a market capitalization of 8.53B, placing it among publicly traded companies globally. Its enterprise value stands at 7.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chongqing Genrix Biopharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A has 366.68M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A maintains a current ratio of 5.45, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A's stock has declined approximately 20.42% over the past 52 weeks. The 50-day moving average sits at 24.18, while the 200-day moving average is 26.27.

As of June 30, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A holds 1.86B in cash and equivalents against 1.13B in total debt, resulting in a net debt position of 515.99M. Total book value stands at 1.28B, with working capital of 1.79B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. Class A paid dividends of 0.06 per share.